https://www.myisrnn.org/events-1 daily 0.75 2023-12-14 https://www.myisrnn.org/events-1/4th-biomotors-conference monthly 0.5 2023-12-14 https://www.myisrnn.org/events-1/isrnnevent1 monthly 0.5 2023-04-11 https://www.myisrnn.org/isrnn-articles daily 0.75 2024-06-18 https://www.myisrnn.org/isrnn-articles/the-international-society-of-rna-nanotechnology-and-nanomedicine-isrnn-the-present-and-future-of-the-burgeoning-field-c8ay3 monthly 0.5 2024-06-18 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/ec47a914-513a-4688-be83-a6b29e2ed03a/Capture.PNG ISRNN Articles - Cracking the Code: Enhancing Molecular Tools for Progress in Nanobiotechnology - Abstract Nature continually refines its processes for optimal efficiency, especially within biological systems. This article explores the collaborative efforts of researchers worldwide, aiming to mimic nature’s efficiency by developing smarter and more effective nanoscale technologies and biomaterials. Recent advancements highlight progress and prospects in leveraging engineered nucleic acids and proteins for specific tasks, drawing inspiration from natural functions. The focus is developing improved methods for characterizing, understanding, and reprogramming these materials to perform user-defined functions, including personalized therapeutics, targeted drug delivery approaches, engineered scaffolds, and reconfigurable nanodevices. Contributions from academia, government agencies, biotech, and medical settings offer diverse perspectives, promising a comprehensive approach to broad nanobiotechnology objectives. Encompassing topics from mRNA vaccine design to programmable protein-based nanocomputing agents, this work provides insightful perspectives on the trajectory of nanobiotechnology toward a future of enhanced biomimicry and technological innovation. https://www.myisrnn.org/isrnn-articles/the-international-society-of-rna-nanotechnology-and-nanomedicine-isrnn-the-present-and-future-of-the-burgeoning-field-z84xx monthly 0.5 2022-11-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/2b892949-7c41-42a4-ad92-2961bcfa99cd/thumbnail_image.png ISRNN Articles - Biomotors, viral assembly, and RNA nanobiotechnology: Current achievements and future directions - Abstract The International Society of RNA Nanotechnology and Nanomedicine (ISRNN) serves to further the development of a wide variety of functional nucleic acids and other related nanotechnology platforms. To aid in the dissemination of the most recent advancements, a biennial discussion focused on biomotors, viral assembly, and RNA nanobiotechnology has been established where international experts in interdisciplinary fields such as structural biology, biophysical chemistry, nanotechnology, cell and cancer biology, and pharmacology share their latest accomplishments and future perspectives. The results summarized here highlight advancements in our understanding of viral biology and the structure–function relationship of frame-shifting elements in genomic viral RNA, improvements in the predictions of SHAPE analysis of 3D RNA structures, and the understanding of dynamic RNA structures through a variety of experimental and computational means. Additionally, recent advances in the drug delivery, vaccine design, nanopore technologies, biomotor and biomachine development, DNA packaging, RNA nanotechnology, and drug delivery are included in this critical review. We emphasize some of the novel accomplishments, major discussion topics, and present current challenges and perspectives of these emerging fields. 2022 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). https://www.myisrnn.org/isrnn-articles/the-international-society-of-rna-nanotechnology-and-nanomedicine-isrnn-the-present-and-future-of-the-burgeoning-field monthly 0.5 2024-06-18 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/14d41353-dc3d-4d4b-ba75-94312a9917dd/Screen+Shot+2022-06-24+at+12.59.48+PM+%281%29+copy.jpg ISRNN Articles - The International Society of RNA Nanotechnology and Nanomedicine (ISRNN): The Present and Future of the Burgeoning Field - Abstract The International Society of RNA Nanotechnology and Nanomedicine (ISRNN) hosts an annual meeting series focused on presenting the latest research achievements involving RNA-based therapeutics and strategies, aiming to expand their current biomedical applications while overcoming the remaining challenges of the burgeoning field of RNA nanotechnology. The most recent online meeting hosted a series of engaging talks and discussions from an international cohort of leading nanotechnologists that focused on RNA modifications and modulation, dynamic RNA structures, overcoming delivery limitations using a variety of innovative platforms and approaches, and addressing the newly explored potential for immunomodulation with programmable nucleic acid nanoparticles. In this Nano Focus, we summarize the main discussion points, conclusions, and future directions identified during this two-day webinar as well as more recent advances to highlight and to accelerate this exciting field. https://www.myisrnn.org/news daily 0.75 2023-07-17 https://www.myisrnn.org/news/international-society-of-rna-nanotechnology-and-nanomedicine-isrnn-president-peixuan-guo-named-fellow-of-the-national-academy-of-inventors monthly 0.5 2023-07-17 https://www.myisrnn.org/isrnnhome daily 0.75 2025-01-13 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/8c74da17-fd84-4c59-bab1-2ca68c55af3c/Journal-page-1-500.png Home - Our new official society journal has been online! Congratulations to every participating member You can now submit your manuscript to our society journal using the following link: Click here December 31, 2024 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656623849209-N9I11A68WS2P4PTKB7P7/Screen+Shot+2022-06-24+at+12.59.48+PM.png Home - Welcome! RNA nanotechnology is the bottom-up self-assembly of nanometer-scale architectures made exclusively of RNA and its chemical analogs. This is a growing field with remarkable and continuous progression for more than two decades. The field of RNA nanotechnology is derived from the knowledge gained from many years of dedicated work by the members of the scientific community. The fundamental properties of RNA revealed by this research have been a driving force for the development of RNA nanotechnology. These properties include RNA dynamics, unique physicochemical parameters of RNA, expanded tools for 3D computation, pseudoknot formation and ability for non-canonical base pairings, induced fit, conformational capture, near-neighbor creed, strand breathing, etc. Many RNA scientists who contributed to better understanding and development of these principles have come together to become the core of the ISRNN. RNA can be designed and manipulated with a level of simplicity similar to DNA while displaying versatile structure and enzymatic function attributed to proteins. RNA folds into a large variety of structural and long-range interacting motifs for intra- and inter-molecular interactions that lead to the formation of functional structures. Thanks to the collective effort of the RNA community, the concern of RNA instability in nanotechnology and biomedical applications has now been well addressed. RNA nanoarchitectures are stretchable and shrinkable through multiple repeats like rubber, leading to an unusually high tumor targeting efficiency since their rubber- or amoeba-like deformability enables them to squeeze through leaky vasculature. As they are made from a naturally occurring and ubiquitous biopolymer, RNA nanoparticles remain non-toxic and can be rapidly cleared from the body via renal excretion with little accumulation in organs and tissues in vivo. RNA is negatively charged, which prevents nonspecific binding to negatively charged cell membranes and further internalization which avoids undesired immune responses. The ultra-high thermodynamic stability of RNA makes it possible to serve as material for logic gates, resistive memory, sensor operations, and NEM devices. The purpose of this society is to promote information exchange, enhance collaboration, and trigger the generation of new findings in the field of RNA nanotechnology. It was predicted many years ago that RNA therapeutics would be the third milestone in drug development, and the recent approval of several RNA drugs by the FDA and the broad application of the Covid mRNA vaccine has ushered in the spring of RNA nanotechnology and RNA therapeutics. Extension of current application areas, exponential increase in the number of published articles, and the launching of dedicated new journals in the RNA and RNAi fields are solid evidence of this advancement. The application of RNA nanoparticles (NPs) in drug delivery especially for the treatment of various cancers has uplifted the popularity of RNA nanotechnology. Peixuan Guo, ISRNN President Kirill Afonin, ISRNN Vice President https://www.myisrnn.org/aboutisrnn daily 0.75 2022-09-06 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/74e5ee05-ecad-4487-81ab-c648a323ee29/Final+logo+isrnn+copy.png About - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.myisrnn.org/council-members daily 1.0 2024-01-03 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1655385890390-1H09KS6TR3JOB3T6R8X9/woodson_NWK9918_web.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1655385917760-0T47QJ00JVI4MDD7DE0I/Guo.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525070668-KCNR219OUMCLACO5RJK2/afonin_kirill.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525318368-8EVMY9OKBZH0O9ICNPJS/Carlo+M+Croce+M.D..jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525478476-3HVP6HQXLMFKHLMYQB7P/Eric+Westhof.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525614510-JU9JLZ4JTKRBVD34XXL8/Mark+Evers.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525979686-ZM8BZMXJ8FAKE1HKTQXF/ChenShiJie.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656598650583-X74P43OX71I46G4Z2I99/Yuri%2BLyubchenko.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656601534703-18KDGTRJ0AKJXVSFF12L/Mark%2BBathe.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656606396501-BLQFO6G5OOCRC8AZQ07T/Tushar%2BPatel.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1659134143869-IMF90XLRX9664V0A99DL/Zhang+photo.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1663688127212-G2YKZV720SF8CKNVGQNU/J%25c3%25b8rgen%2520Kjems+copy.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1663688946281-COPSZE61AEJ9BX0SVTFN/image0.jpeg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1663689251225-W1OV8W116XJ8ITYNB22K/136191_Sood_A_02.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/23d703ad-f7ab-4f67-8fe8-906ad8c9d948/shapiro-bruce.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/7e11e692-dbe9-4e20-8325-75ceb8ccffc1/thumbnail_image002.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/bf8d884b-6ec3-42f5-a9ba-7079416d775f/saito.JPG Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/b37119e5-3d4d-4106-a2bd-27aef6e3daaa/john-rossi.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/37ceb649-ebd0-41c3-8943-f807ce6e6fab/8.29.17_ndias_luc_jaeger.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/ef481c26-1a07-47e9-a051-79e4279ab709/Marina+Dobrovolskaia.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/afe4d554-4be6-4e0e-b6e2-8f0495ee941c/Nils-Walter-May-2020-e1590068140825.png Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/79664ad4-99d2-4edc-842e-c50b952cc7c1/Hammond_HeadShot-4.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/cab4bd92-9425-4e84-9183-cb02c9e811dc/Robert+Batey.JPG Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/e0b60f91-e9eb-4522-a39d-cd2e157a06ae/Xing-Jie-Liang+4.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/2170f6e8-da71-4c95-9ef9-99085e12c554/Jong+Bum+Lee+%28Picture%29.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/e846ea5d-b9e8-4132-ba71-ad40ba43f52a/Wayne+Miles+%281%29.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/c5945bdf-d392-4132-b548-5794805e43bb/achworos-300x300.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/31e904bd-5e37-4006-8e82-502accd54f4a/gorenstein_david.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/4b81fe20-de96-4cdb-bc68-74b3599008dd/ESA_2015_LK_129_cut.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/b294e681-cb5d-457a-a481-286a5e24509a/download.jfif Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/479d7144-7207-45af-9877-0f181ef4a0d3/1661476577628.jfif Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/8badffaf-735b-4fe1-9e1a-43a79b613dbf/profile-photo.jfif Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/4b2580a6-5ffc-41a7-9f7a-e5a9c8fe601f/daxiang+cui.jpg Council Members https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/c2ef2a27-de32-420c-90d0-918c95b60130/Emil.png Council Members https://www.myisrnn.org/contact daily 0.75 2022-09-06 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/98a49f44-1481-4307-b5ef-23810661b0b3/Final+logo+isrnn+copy.png Contact - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.myisrnn.org/membership-benefits daily 0.75 2022-09-08 https://www.myisrnn.org/dr-peixuan-guo-isrnn daily 0.75 2025-03-26 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/83bd5c7e-b2b4-4ed0-bb3b-e593e4d68959/Guo_innovator.jpg Dr. Peixuan Guo - Dr. Peixuan Guo Email: guo.1091@osu.edu Professional Website Dr. Peixuan Guo received his Ph.D. in Microbiology and Genetics with training in biophysics from the University of Minnesota in 1987. He was a postdoc at NIH before joining Purdue University as an assistant professor in 1990, tenured in 1993, full Professor in 1997, and was honored as a Purdue Faculty Scholar in 1998. He founded two Interdisciplinary Graduate Programs and established a NIH Nanomedicine Development Center at Purdue. He was recruited to University of Cincinnati as the Dane & Mary Louise Miller Endowed Chair of Biomedical Engineering in 2007, and was Director of the NIH Nanomedicine Development Center relocated from Purdue to University of Cincinnati. He moved to University of Kentucky as William Farish Endowed Chair in Nanobiotechnology in 2012, and was the UK Director of Nanobiotechnology Center. In Jan 2016, he joined The Ohio State University College of Pharmacyas the first Sylvan G. Frank Endowed Chair in Pharmaceutics and Drug Delivery Systems. He was recruited in collaboration with Ohio State’s Dorothy M. Davis Heart and Lung Research Institute (DHLRI) and will hold a joint appointment in the College of Medicine’s Department of Physiology & Cell Biology. He is also currently the Director of NCI Cancer Nanotechnology Platform Partnership Program in RNA Nanotechnology for Cancer Therapy, and the Director of Center for RNA Nanobiotechnology and Nanomedicine. He constructed the first viral DNA packaging motor in vitro (PNAS, 1986), discovered phi29 motor pRNA (Science, 1987), assembled infectious dsDNA viruses (J Virology, 1995), discovered pRNA hexamer (Mol Cell, 1998, featured in Cell), and pioneered RNA nanotechnology (Mol Cell, 1998, JNN, 2003; Nano Letter., 2004, 2005; Nature Nanotechnology 2010, 2011). His lab built a dual imaging system to detect single-fluorophores (EMBO J, 2007; RNA, 2007), incorporated the phi29 motor channel into a lipid membrane (Nature Nanotechnology, 2009) for single molecule sensing with potentials for high throughput dsDNA sequencing. Recently, his lab discovered a third class of biomotor using revolution mechanism without rotation. He received the Pfizer Distinguished Faculty Award in 1995; the Purdue Faculty Scholar award in 1998; the Purdue Seed Award in 2004, 2005, and 2007; the Lions Club Cancer Research Award in 2006; and COV Distinguished Alumni of the University of Minnesota in 2009, and many other awards for research excellence. He is an editor or board member of five nanotech journals. His work has been reported hundreds of times over the radio or TV such as ABC and NBC, and featured in Newsletters or websites of NIH, NSF, MSNBC, NCI and ScienceNow etc. He was a member of two prominent national nanotech initiatives sponsored by NIST, NIH, NSF and National Council of Nanotechnology; director of one NIH Nanomedicine Development Center from 2006 to 2011; member of the NIH NDC Steering Committee from 2006-2010; NIH/NCI intramural site-visit Review Panel at 2010 and 2014; Panelist for DOD-US Army, Navy & Air Force Joined Medical Program in 2003; member of the Examination and Review Panel (Oversea Expert) of the Chinese Academy of Sciences since 2014. In 2021, he was named the Innovator of the Year at The Ohio State University and it was announced in 2022 that he had been elected as a Fellow for the National Academy of Inventors. https://www.myisrnn.org/dr-kirill-a-afonin daily 0.75 2022-11-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525070668-KCNR219OUMCLACO5RJK2/afonin_kirill.jpg Dr. Kirill A. Afonin - Dr. Kirill A. Afonin Email: kafonin@uncc.edu Professional Website I was born in Leningrad, U.S.S.R. but grew up in Saint Petersburg, Russian Federation. I graduated from Saint Petersburg State University with an M.S. in Chemistry, followed by a Ph.D. in Photochemistry earned from Bowling Green State University, Ohio. In addition to my doctoral degree, received in 2008, I also obtained a Graduate Certificate in Bioinformatics, Proteomics/Genomics from a joint program between Bowling Green State University, Medical University of Ohio, and University of Toledo, Ohio. In the following three years, I completed a Postdoctoral Fellowship in Chemistry and Biochemistry in Luc Jaeger’s lab at the University of California Santa Barbara. In 2011, I was invited as a Research Fellow to join the group of Bruce Shapiro at the National Cancer Institute, NIH where I established and managed an experimental branch within the Computational RNA Structure Group. I started my tenure-track appointment as an Assistant Professor at UNC Charlotte in 2015 and was promoted to Associate Professor in 2019 and to Professor in 2021. Starting with my doctoral research, under the supervision of Neocles Leontis, I focused my efforts on studying RNA biology and nanotechnology with potential diagnostic and therapeutic applications to biomedicine. My interdisciplinary research experience includes extensive use of both computational and experimental techniques for modeling, prediction, engineering, and characterization in vitro and in vivo of natural and artificial nucleic acid-based structures. https://www.myisrnn.org/sarah-woodson daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/0ea42240-16dd-4099-a470-dba8484bbb3d/woodson_NWK9918_web.jpg https://www.myisrnn.org/dr-carlo-croce daily 0.75 2022-06-30 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/0ea42240-16dd-4099-a470-dba8484bbb3d/woodson_NWK9918_web.jpg Dr. Carlo Croce - Sarah Woodson body copy https://www.myisrnn.org/what-is-rna-nanotechnology-isrnn daily 0.75 2022-07-13 https://www.myisrnn.org/xiaoting-zhang daily 0.75 2022-11-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1659134143869-IMF90XLRX9664V0A99DL/Zhang+photo.jpg Xiaoting Zhang - Dr. Xiaoting Zhang Email: zhangxt@ucmail.uc.edu Professional Website Dr. Xiaoting Zhang is a professor of Cancer Biology and Thomas Boat Endowed Chair at the University of Cincinnati College of Medicine. Dr. Zhang received his Ph.D. in Molecular Biology from the University of Iowa, followed by postdoctoral studies with Dr. Robert G. Roeder at Rockefeller University. Dr. Zhang is a leading researcher at the forefront of both breast cancer and RNA nanotechnology fields and published studies in high-impact journals such as Mol Cell, PNAS, JBC, Cancer Research, EMBO J, ACS Nano, RNA Nanotechnology and Therapeutics by CRC press, Cell Reports, etc. Notably, he is the editor of the book “Estrogen Receptor and Breast Cancer (1st ed, 2019)” per invitation by Springer Nature to celebrate the 60th anniversary of the discovery of ER. Dr. Zhang has 20+ years of research experience in cancer biology leading the studies that discovered the estrogen receptor coactivator MED1 and its crosstalk with HER2 as a novel key mechanism in breast cancer metastasis and treatment resistance, and is the inventor of a patented RNA nanotechnology approach to overcome breast cancer metastasis and therapy resistance. Dr. Zhang’s lab has been supported by grants and awards from major federal, national and local breast cancer funding agencies including NCI, DoD, American Cancer Society and Komen for the Cure Foundation, Breast Cancer Alliance, Ride Cincinnati Foundation, and Ohio Cancer Research. He is a regularly invited grant reviewer for NCI, DoD, ACS, Komen, National Science Foundation, AACR, AAAS, as well as international grant organizations such as Hong Kong Research Grant Council, the Marsden Fund of Royal Society of New Zealand, and Worldwide Cancer Research. Dr. Zhang is the director of the Breast Cancer Research Program (BCRP) which is composed of 20 outstanding basic, clinical, and translational research groups at the University of Cincinnati and Cincinnati Children’s Hospital Medical Center. He has been awarded the first Joanne and Michael Masin Young Investigator award, Hormone Research Foundation C. H. Li Memorial Scholar Award, Susan G. Komen Career Catalyst Award, DoD Idea Award, and named an American Cancer Society Research Scholar. Dr. Zhang is a founding council member, treasurer, and chair of the nomination committee of the ISRNN. https://www.myisrnn.org/jorgen-kjems daily 0.75 2022-09-20 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/03c99865-2ab3-4d5d-a7f9-93017cd66cab/J%C3%B8rgen Jørgen Kjems - Dr. Jørgen Kjems Email: jk@mbg.au.dk Dr. Kjems studied chemistry and physics at Aarhus University from where he received his PhD degree in field of RNA chemistry in 1989. After being a post-doctoral fellow at Harvard Medical School, Boston, USA 1989-1990 and at MIT, Cambridge, USA 1990-1991 JK returned to Department for Molecular Biology, University of Aarhus where he became associated professor in 1994. In 2003 he was appointed as full professor in Molecular Biology and Nano Science and took part in the establishment of the Interdisciplinary Nanoscience Centre (iNANO). From 2010-2016 JK was PI for the Lundbeck Centre, LUNA, that focused on nanomedicine. In 2013 Dr. Kjems co-founded a new Center for Integrative Sequencing (iSEQ) at Aarhus University that focuses on next generation sequencing and bioinformatics analysis of sequencing and RNA profiling data. In the period of 2014-2018 he has headed the Interdisciplinary Nanoscience Centre (iNANO). iNANO is a truly interdisciplinary, physically assembled, entity at University of Aarhus with active participation of about 50 senior researchers, 60 junior researchers and 150 PhD students and from 2017 he headed the Danish National Research Foundation for Centre for Cellular Signal Patterns, CellPat. Dr. Kjems has received several prizes including the Novo Nordisk Prize in 2018. He co-founded to start-up companies Nanoference and Aloop Therapeutics focusing on RNA therapeutics. He has published around 400 international research papers that hold 35.000 citations. His research competencies include RNA drug delivery, bioimaging, RNA biomarkers and therapeutics, aptamer technology, noncoding RNA role in disease, RNA and protein-based nanotechnologies. https://www.myisrnn.org/anil-sood daily 0.75 2022-10-07 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1663689251225-W1OV8W116XJ8ITYNB22K/136191_Sood_A_02.jpg Anil Sood - Dr. Anil K. Sood Email: asood@mdanderson.org Dr. Anil K. Sood is Professor in the Department of Gynecologic Oncology and Reproductive Medicine at the UT MD Anderson Cancer Center. He is co-director of the Center for RNA Interference and Non-Coding RNA at the M. D. Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program and co-leads the Ovarian Cancer Moonshot Program. Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill. A major and consistent theme of his scientific research has been on understanding human cancer biology and converting lab discoveries into novel therapeutics. His research group has made several seminal research contributions in the fields of tumor microenvironment, nanomedicine, and neuroendocrine effects on cancer biology. Dr. Sood has received recognition for his research accomplishments including the Hunter Award, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. He is an elected member of the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS), and the Association of American Physicians (AAP). Dr. Sood was selected as an American Cancer Society Research Professor in 2017 and was elected to the National Academy of Medicine (NAM) in 2021. https://www.myisrnn.org/tushar-patel daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656606396501-BLQFO6G5OOCRC8AZQ07T/Tushar%2BPatel.jpg Dr. Tushar Patel - Dr. Tushar Patel Email: Patel.Tushar@mayo.edu Professional Website Research in the laboratory of Tushar C. Patel, M.B., Ch.B., focuses on liver epithelial cell biology, with an emphasis on understanding the role and regulation of noncoding RNA genes in the pathogenesis of liver and biliary tract cancers. An area of emphasis is the study of cellular and molecular mechanisms by which dysregulation of cell survival signaling pathways contributes to disease pathogenesis in hepatobiliary cancers. Dr. Patel is particularly interested in the roles of extracellular vesicles and extracellular RNA in fundamental processes involved in liver cancers. In conjunction with the Extracellular RNA Communication Consortium, funded by the National Institutes of Health (NIH) Common Fund, Dr. Patel and his group are exploring novel biomarkers. Based on this research, they are developing new treatments and exploring new paradigms of disease. https://www.myisrnn.org/david-lilley daily 0.75 2022-11-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/7e11e692-dbe9-4e20-8325-75ceb8ccffc1/thumbnail_image002.jpg David Lilley - Professor David M.J. Lilley FRS Email: d.m.j.lilley@dundee.ac.uk Professional Website School of Life Sciences, University of Dundee, Dundee, UK Visiting professor Xiamen University, Nankai University and the University of the Chinese Academy of Sciences. Professor Lilley has a long-standing interest in nucleic acid structure and function (both DNA and RNA) going back more than forty years. He was the first to solve the structure of the Holliday junction in DNA, and has made extensive studies of its interaction with junction-resolving enzymes. He has solved the crystal structure of a complex with eukaryotic GEN1 resolving enzyme. Lilley has had a long interest in the structures and mechanisms of RNA catalysis. He has solved crystal structures of the twister, TS and pistol ribozymes, and defined their chemical mechanisms. Most recently he has determined the structure of a methyltransferase ribozyme, and shown that it employs a remarkably sophisticated catalytic mechanism that involves nucleobase-mediated general acid catalysis. His lab has solved crystal structures of seven different riboswitches, the most recent being a new NAD+ riboswitch. Lilley has made a detailed study of the structure and folding of the k-turn motif. This is arguably now the best understood structural motif in RNA. Recently he has shown how N6-methylation of a critical adenine blocks the key first stages of box C/D snoRNP assembly. Professor Lilley is an elected fellow of the Royal Society. https://www.myisrnn.org/luc-jaeger daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/6ce0a46e-e912-4390-9157-f6d8d3d78851/8.29.17_ndias_luc_jaeger.jpg Dr. Luc Jaeger - Dr. Luc Jaeger Email: jaeger@chem.ucsb.edu Luc Jaeger is a professor of chemistry and biochemistry at the University of California, Santa Barbara (UCSB) where he is affiliated to the Biomolecular Science and Engineering program at UCSB. His present research interests focus on ribonucleic acid (RNA), one of the most important biopolymers on which life is based on Earth. By addressing scientific questions pertaining to RNA structural evolution and rational design, the emergence of complexity in biological systems and the origins of life, his research encompasses fields as diverse as RNA biochemistry and biophysics, astrobiology, nucleic acid nanotechnology, material sciences, synthetic biology and nanomedicine. Professor Jaeger is also interested in the dialogue between science and religion, an interest at work in his current research project at the NDIAS. He is the author or co-author of more than seventy research articles published in renowned international scientific journals as well as several scientific book chapters. He is also the recipient of numerous grants and awards, including an ULP-NIBH (National Institute of Bioscience and Human Technology and Information Services) grant for work in Japan and a UCSB Junior Faculty Research Incentive Award. Professor Jaeger’s research has been supported by major grants from the National Science Foundation, the National Institutes of Health, and, more recently, the National Aeronautics and Space Administration. From 2011 to 2013 he served as a member of the Advisory Board of the John Templeton Foundation. https://www.myisrnn.org/marina-dobrovolskaia daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/496e2ed8-2979-497f-bb84-0658e85489d6/Marina+Dobrovolskaia.jpg Dr. Marina Dobrovolskaia - Dr. Marina Dobrovolskaia Email: marina@mail.nih.gov Dr. Dobrovolskaia is Laboratory co-Director, Director of Operations and the Head of immunology section at the Nanotechnology Characterization Laboratory (NCL). In her role as the Director of Operations, Dr. Dobrovolskaia leads the NCL operations to provide preclinical nanoparticle characterization services to the nanotechnology research community, advance the translation of promising nanotechnology concepts from bench to the clinic, and contribute to the education of the next generation of scientists in the field of preclinical development of nanotechnology-based products, the activities emphasized in the NCL mission. She also directs the performance of immunology, client relations and administrative sections of the NCL. Closely integrated functioning of these sections plays a critical role in advancing the NCL’s key strategic goals, and in supporting the missions of the Frederick National Laboratory for Cancer Research. In her role as the Head of the immunology section, Dr. Dobrovolskaia leads a team conducting preclinical studies to monitor nanoparticles’ toxicity to the immune system both in vitro and in vivo using variety of immune function animal models. Prior to joining the NCL, Dr. Dobrovolskaia worked as a Research Scientist in a good laboratory practice (GLP) laboratory at PPD Development, Inc. in Richmond, VA, where she was responsible for the design, development and validation of bioanalytical ligand-binding assays to support pharmacokinetic and toxicity studies in a variety of drug development projects. She received her M.S. degree from the Kazan State University in Russia; Ph.D. from the N.N. Blokhin Cancer Russian Research Center of the Russian Academy of Medical Sciences in Moscow, Russia, and M.B.A. from the Hood College in Frederick, MD. Since 2016, she is also a member of the Project Management Institute and a certified Project Management Professional. https://www.myisrnn.org/mark-bathe daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656601534703-18KDGTRJ0AKJXVSFF12L/Mark%2BBathe.jpg Dr. Mark Bathe - Dr. Mark Bathe Email: mbathe@mit.edu Lab Website Professor Bathe obtained his Bachelor’s, Master’s, and Doctoral Degrees from MIT working in the Departments of Mechanical, Chemical, and Biological Engineering before moving to the University of Munich to carry out his postdoctoral research. He returned to MIT in 2009 to join the faculty in the Department of Biological Engineering, where he runs an interdisciplinary research group focused on the targeted delivery of therapeutic nucleic acids and vaccines, phenotypic profiling of neuronal circuits involved in psychiatric disease, and engineering nucleic acid materials for highly parallel molecular computing and massive data storage. Professor Bathe is Co-Director of the MIT New Engineering Education Transformation, an Associate Member of the Broad Institute of MIT & Harvard, and a Member of the HMS Initiative for RNA Medicine. https://www.myisrnn.org/paula-hammond daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/79664ad4-99d2-4edc-842e-c50b952cc7c1/Hammond_HeadShot-4.jpg Dr. Paula Hammond - Dr. Paula Hammond Email: hammond@mit.edu Professional Website Paula T. Hammond is Institute Professor at the Massachusetts Institute of Technology and the Head of the Department of Chemical Engineering. She is a member of MIT’s Koch Institute for Integrative Cancer Research, the MIT Energy Initiative, and a founding member of the MIT Institute for Soldier Nanotechnology. The core of her work is the use of electrostatics and other complementary interactions to generate functional materials with highly controlled architecture. Her research in nanomedicine encompasses the development of new biomaterials to enable drug delivery from surfaces with spatio-temporal control. She also investigates novel responsive polymer architectures for targeted nanoparticle drug and gene delivery, and has developed self-assembled materials systems for electrochemical energy devices. Professor Paula Hammond was elected into the National Academy of Science in 2019, the National Academy of Engineering in 2017, the National Academy of Medicine in 2016, and American Academy of Arts and Sciences in 2013. She is one of only 25 distinguished scientists elected to all three national academies. She won the ACS Award in Applied Polymer Science in 2018, and she is also the recipient of the 2013 AIChE Charles M. A. Stine Award, which is bestowed annually to a leading researcher in recognition of outstanding contributions to the field of materials science and engineering, and the 2014 AIChE Alpha Chi Sigma Award for Chemical Engineering Research. She was selected to receive the Department of Defense Ovarian Cancer Teal Innovator Award in 2013, which supports a single visionary individual from any field principally outside of ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. By developing degradable electrostatically assembled layer-by-layer (LbL) thin films that enable temporal and even sequential controlled release from surfaces, Paula Hammond pioneered a new and rapidly growing area of multicomponent surface delivery of therapeutics that impacts biomedical implants, tissue engineering and nanomedicine. A key contribution is her ability to introduce not only controlled release of sensitive biologics, but her recent advances in actually staging the release of these drugs to attain synergistically timed combination therapies. She has designed multilayered nanoparticles to deliver a synergistic combination of siRNA or inhibitors with chemotherapy drugs in a staged manner to tumors, leading to significant decreases in tumor growth and a great lowering of toxicity. The newest developments from her lab offer a promising approach to messenger RNA (mRNA) delivery, in which she creates pre-complexes of mRNA with its capping protein and synthesized optimized cationic polypeptides structures for the co-complexation and stabilization of the nucleic acid-protein system to gain up to 80-fold increases in mRNA translation efficiency, opening potential for vaccines and immunotherapies. Professor Hammond has published over 320 papers, and over 20 patent applications. She is the co-founder and member of the Scientific Advisory Board of LayerBio, Inc. and a member of the Scientific Advisory Board of Moderna Therapeutics. https://www.myisrnn.org/dr-bruce-shapiro daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/23d703ad-f7ab-4f67-8fe8-906ad8c9d948/shapiro-bruce.jpg Dr. Bruce Shapiro - Dr. Bruce Shapiro Email: shapirbr@mail.nih.gov Professional Website Dr. Shapiro received his Ph.D. in computer science from the University of Maryland in 1978, with undergraduate work in mathematics and physics. During his association with the NIH, Dr. Shapiro did extensive work in image processing, nucleic acid structure prediction and analysis, and computational and experimental nanobiology, leading to several novel algorithms, computer systems, experimental techniques and discoveries in RNA biology. His interests included RNA nanobiology, understanding the relationships between RNA structure and function, and the use of parallel high-performance computer architectures to solve problems related to RNA computational and experimental biology and molecular modeling. Dr. Shapiro retired as a Senior Investigator in 2021 and is now an NCI Scientist Emeritus. https://www.myisrnn.org/xing-jie-liang daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/e0b60f91-e9eb-4522-a39d-cd2e157a06ae/Xing-Jie-Liang+4.jpg Dr. Xing-Jie Liang - Dr. Xing-Jie Liang Email: liangxj@nanoctr.cn Professional Website Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA and Academician member of US national academy of sciences) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. He is also leading a group on nanopharmaceuticals at the CAS Center for Excellence in Nanoscience and Chief Lecture Professor of Nanobiology at University of Chinese Academy of Sciences. Dr. Xing-Jie Liang is current editor-in-chief of Current Drug Delivery, deputy Editor-in-Chief of Biophysics Report and Associate Editor of Biomaterials, Advisory Board Member of ACS Nano. He is also current editorial board member of Bioconjugate Chemistry, Biomaterials Research, Theranostics and guest editor of Biotechnology Advances. Dr. Liang was awarded with the Distinguished Young Scientists Grant by National Natural Science Foundation in 2012 and honored with the People's Republic of China State Council Special Allowance in 2010 as well as National Youth Science and technology innovation leader in 2017. Prof. Liang published over 280 peer-reviewed papers including articles in “Nature Nanotechnology https://www.myisrnn.org/yizhou-dong daily 0.75 2023-02-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/a2a67ba9-032e-48aa-b13b-be0d4d80353a/Yizhou-Dong-1022x1024.jpg Dr. Yizhou Dong - Dr. Yizhou Dong Email: yizhou.dong@mssm.edu Professional Website Yizhou Dong, PhD, is a Professor with the Icahn Genomics Institute, the Marc and Jennifer Lipzhultz Precision Immunology Institute (PrIISM), and the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai. Dr. Dong’s research focuses on the design and development of nanoparticle delivery systems and RNA therapeutics for the treatment of cancer, genetic disorders, and infectious diseases. His lab will integrate their specialty in pharmaceutics, pharmaceutical chemistry, biomedical engineering, materials formulation, and animal studies to design novel therapeutic medicines and uncover their mechanisms of actions. Recognized as a leader in the lipid nanoparticle (LNP) field, Dr. Dong has authored over 70 papers and has over 50 patents. Several of his inventions have been licensed and are currently under development as drug candidates for clinical trials. Dr. Dong is the recipient of Young Innovator in Cellular and Molecular Bioengineering from the Biomedical Engineering Society, Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences (NIGMS), Ohio State Early Career Innovator of the Year, and The American Association of Pharmaceutical Scientists (AAPS) Emerging Leader Award. He was also recently elected fellow of The American Institute for Medical and Biological Engineering (AIMBE). Dr. Dong received his B.S. in Pharmaceutical Sciences from Peking University, Health Science Center and his M.S. in Organic Chemistry from Shanghai Institute of Organic Chemistry. In 2009, he received his Ph.D. degree in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill (UNC-CH) and then did a postdoctoral fellowship in the lab of Robert Langer and Daniel Anderson at MIT. He was appointed as an Assistant Professor at OSU in 2014 and promoted to Associate Professor in 2018. He joined Mount Sinai as a tenured professor in 2022. https://www.myisrnn.org/thomas-d-schmittgen daily 0.75 2023-04-11 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/8badffaf-735b-4fe1-9e1a-43a79b613dbf/profile-photo.jfif Dr. Thomas D Schmittgen - Dr. Thomas D Schmittgen Email: tschmittgen@ufl.edu Professional Website Thomas D. Schmittgen, Ph.D. is a professor and Chair in the Department of Pharmaceutics at the University of Florida in Gainesville and is the V. Ravi Chandran Professor of Pharmaceutical Sciences. Dr. Schmittgen holds both undergraduate (Pharmacy) and graduate degrees (Pharmaceutics) from the Ohio State University. He was a National Research Service Award (NIH) postdoctoral fellow at the University of Southern California from 1992-1995. He served on the faculty at Washington State University College of Pharmacy from 1995-2002. Dr. Schmittgen returned to the Ohio State University in 2002 where he remained on the faculty for 13 years, serving as chair of the Division of Pharmaceutics from 2000-2015. Dr. Schmittgen was hired at the University of Florida in 2015 through the UF Preeminence Initiative. https://www.myisrnn.org/carlo-croce daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525318368-8EVMY9OKBZH0O9ICNPJS/Carlo+M+Croce+M.D..jpg Dr. Carlo Croce - Dr. Carlo Croce Email: croce.5@osu.edu OSU Website Carlo Maria Croce is an Italian–American professor of medicine at The Ohio State University, specializing in oncology and the molecular mechanisms underlying cancer. He is currently they John W. Wolfe Chair in Human Cancer Genetics and a member of the Cancer Biology Program at the OSUCCC – James, where he studies the molecular changes in genes that lead to cancer. He is particularly interested in the early changes of malignancy and how they might serve as targets for new treatment and preventive agents. Croce graduated in 1969 summa cum laude in medicine and Latin from La Sapienza University of Rome. His research career in the United States began the following year at the Wistar Institute of Biology and Anatomy in Philadelphia. In 1980, Croce was named Wistar Professor of Genetics at the University of Pennsylvania and associate director of the Wistar Institute, and from 1988-1991 he was director of the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine. In 1991, Croce was named Director of the Kimmel Cancer Center at Jefferson Medical College at the Thomas Jefferson University in Philadelphia. https://www.myisrnn.org/dr-eric-westhof daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525478476-3HVP6HQXLMFKHLMYQB7P/Eric+Westhof.jpg Dr. Eric Westhof - Dr. Eric Westhof Email: eric.westhof@ibmc-cnrs.unistra.fr Professional Website Wikipedia Page Éric Westhof is a French biochemist. He is a member of the Academie des sciences, head of Education and Training (DEF), and a member of the Board of Directors of the "La Main à la pâte" Foundation. He is professor emeritus of structural biochemistry at the University of Strasbourg at the Institute of Molecular and Cellular Biology. After obtaining a bachelor's degree in physical sciences from the University of Liège, he carried out research work at the Regensburg Universität (Germany) on a EURATOM grant with a view to obtaining a doctorate from the University of Liège in 1974. He then became a research associate (on a Fulbright-Hays fellowship) at the University of Wisconsin until 1977 in Professor M. Sundaralingam's laboratory. Thanks to an EMBO grant, he then established himself in 1981 at the Institute of Molecular and Cellular Biology of the Centre national de la recherche scientifique (IBMC-CRNS), affiliated with the Université Louis Pasteur (ULP-Strasbourg) in France. In 1984, he obtained a position as a research fellow (CR1) and has been a professor of structural biochemistry since 1988. From 2005 to 2016, he was director of the CNRS Research Unit "Architecture and Reactivity of RNA" at the Institute of Molecular and Cellular Biology (IBMC), where he was director from 2006 to 2016. From 2003 to 2007 he was chairman of the Research Commission of the Faculty of Life Sciences of Louis Pasteur University, where he was an elected member of the Scientific Council from 2002-2006. He was then elected vice president research and doctoral training (2007-2008). Together with Alain Beretz, he is involved in the merger of the three Strasbourg universities and becomes vice-president research and doctoral training at the University of Strasbourg between 2009 and 2012. Eric Westhof is executive editor of RNA journal (CSHP), Nucleic Acids Research (OUP), and the Journal of Molecular Recognition (Wiley). https://www.myisrnn.org/dr-mark-evers daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525614510-JU9JLZ4JTKRBVD34XXL8/Mark+Evers.jpg Dr. Mark Evers - Dr. Mark Evers Email: mark.evers@uky.edu University of Kentucky Website https://www.myisrnn.org/yuri-lyubchenko daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656598650583-X74P43OX71I46G4Z2I99/Yuri%2BLyubchenko.jpg Dr. Yuri Lyubchenko - Dr. Yuri Lyubchenko Email: ylyubchenko@unmc.edu University of Nebraska Website https://www.myisrnn.org/shi-jie-chen daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1656525979686-ZM8BZMXJ8FAKE1HKTQXF/ChenShiJie.jpg Shi-Jie Chen - Dr. Shi-Jie Chen Email: ChenShi@missouri.edu Professional Website https://www.myisrnn.org/shi-jie-chen-1 daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1663688946281-COPSZE61AEJ9BX0SVTFN/image0.jpeg Shyam Rele - Dr. Shyam Rele Email: shyamrele@gmail.com https://www.myisrnn.org/emil-khisamutdinov daily 0.75 2023-12-21 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/c2ef2a27-de32-420c-90d0-918c95b60130/Emil.png Emil Khisamutdinov - Dr. Emil Khisamutdinov Email: kemil@bsu.edu Professional Website About Dr. Emil Khisamutdinov Before joining Ball State in 2014, he spent two years at the University of Kentucky as a PostDoc in the lab of a well-known scientist in the RNA nanotechnology field, prof. Peixuan Guo. College Experience He teaches Biochemistry courses and runs a small BioNanoTechnology Research Laboratory. His major was in bioorganic and biochemistry. He received a Ph.D. degree from Bowling Green State University, where he studied DNA damage by photo-sensitive drugs and elucidated structure and thermodynamic stability of ribosomal RNA motifs. He obtained his M.S. and B.S. in chemistry from the National University of Uzbekistan. https://www.myisrnn.org/hirohide-saito daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/bf8d884b-6ec3-42f5-a9ba-7079416d775f/saito.JPG Hirohide Saito - Dr. Hirohide Saito Email: hsaito-g@cira.kyoto-u.ac.jp Professional Website Kyoto University Website About Dr. Hirohide Saito Dr. Saito is professor at Kyoto University. He obtained his Masters of Science in the Department of Chemistry and Biotechnology Graduate School of Engineering from The University of Tokyo in 1999. He then went to complete his PhD in the Department of Chemistry and Biotechnology Graduate School of Engineering at The University of Tokyo. Research Overview Creation of RNA-based synthetic life systems RNA-Protein (RNP) complex plays a central role in gene expression by controlling processes such as translation, transcription, and RNA processing. With this background, they came up with the idea that the understanding of the necessary factors to form the RNP such as RNA sequences and structures would enable them to artificially create RNP complexes to control molecular mechanisms and cell fates. With this idea of synthetic biology, they are working on the elucidation of the programming mechanism of cells and precise cell fate control through the development of new technologies to understand, control and create RNP-based life systems. By utilizing cell type-specific RNA and protein markers, they are working on the following themes in order to develop technologies that control molecular mechanisms specific to target cells and apply them to medical research. 1. Construction of artificial RNA systems which detect intracellular information and regulate cell-fate. 2. Development of RNA switch technologies that safely and precisely identify and recognize the target cells. 3. Construction of RNP nanostructures functioning in cells and realizing RNP spatiotemporal control. In addition, they are engaging in the following themes in order to elucidate and control the molecular systems in the cell controlled by RNA and RNP. 4. Understanding of the molecular mechanism of post-transcriptional regulation in cell programming. 5. Development of new technologies for the comprehensive analysis of RNA-protein interaction. In his group, each graduate student will work on original research themes and acquire skills and knowledge of synthetic biology, molecular biology, and cell engineering https://www.myisrnn.org/john-j-rossi daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/b37119e5-3d4d-4106-a2bd-27aef6e3daaa/john-rossi.jpg John J. Rossi - Dr. John J. Rossi Email: jrossi@coh.org City of Hope Website John Rossi, Ph.D., the Lidow Family Research Chair and professor and chair of the Department of Molecular and Cellular Biology, is widely regarded as a world leader in the development of RNA interference and in clinical research involving nucleic acids for the treatment of various diseases. Currently, he is focusing on enhancing the intracellular efficacy of ribozymes, small RNAs and siRNAi, and their application to gene therapy for HIV and cancer. In 2019, he received the 2019 Outstanding Achievement Award presented by the American Society of Gene and Cell Therapy (ASGCT). The award is presented annually to the ASGCT member who has achieved pioneering research success and a lifetime of significant contributions to the field of gene and cell therapy. It is the society’s highest honor. Dr. Rossi is the editor in chief of Molecular Therapy-Nucleic Acids and deputy editor of Molecular Therapy. He has authored more than 275 peer-reviewed papers and more than 70 book chapters. He is also founding president of Oligonucleotide Therapeutics Society. Dr. Rossi joined City of Hope in 1980 after receiving his Ph.D. in microbial and eukaryotic genetics at the University of Connecticut. https://www.myisrnn.org/nils-g-walter daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/afe4d554-4be6-4e0e-b6e2-8f0495ee941c/Nils-Walter-May-2020-e1590068140825.png Nils G. Walter - Dr. Nils G. Walter Email: nwalter@umich.edu Professional Website University of Michigan Website Dr. Walter is the Francis S. Collins Collegiate Professor of Chemistry, Biophysics, and Biological Chemistry at the University of Michigan, Ann Arbor. Research in the Nils Walter Lab focuses on non-coding RNA through the lens of single molecule techniques. He is the Founding Director of the Single Molecule Analysis in real-Time (SMART) Center at Michigan. In addition, Walter is the Founding Co-Director for the University of Michigan Center for RNA Biomedicine whose mission is to enrich the university’s intellectual and training environment around RNA Biomedicine. He is currently an Associate Director for the Michigan Post-baccalaureate Research Education Program (PREP). He received his “Vordiplom” (B.S.) and “Diploma” (Masters) from the Technical University of Darmstadt after performing research with Hans-Günther Gassen [de] on the physicochemical characterization of a protein dehydrogenase enzyme. He is a summa cum laude Dr. Ing. (PhD) graduate from the Technical University of Darmstadt and the Max-Planck-Institute for Biophysical Chemistry where he studied molecular in vitro evolution of DNA and RNA using fluorescence techniques with Nobel laureate Manfred Eigen. For his postdoctoral studies, he turned to RNA enzymes under the guidance of John M. Burke at the University of Vermont. The Nils Walter Lab studies both non-coding RNA and protein-coding RNAs, and how the former control the gene expression of the latter, using tools from biophysics, biochemistry, cell biology, molecular biology and chemical biology. Most prominently, the lab uses leading-edge single molecule and super-resolution microscopy and single-molecule FRET approaches to probe the diverse functional mechanisms of transcriptional and translational riboswitches, the spliceosome, the RNA silencing and RNA interference machinery, ribozymes, as well as devices from DNA nanotechnology, in vitro and in live cells. https://www.myisrnn.org/robert-batey daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/cab4bd92-9425-4e84-9183-cb02c9e811dc/Robert+Batey.JPG Robert Batey - Dr. Robert Batey Email: robert.batey@colorado.edu Professional Website University of Colorado Boulder Dr. Batey https://www.myisrnn.org/jong-bum-lee daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/2170f6e8-da71-4c95-9ef9-99085e12c554/Jong+Bum+Lee+%28Picture%29.jpg Jong Bum Lee - Dr. Jong Bum Lee Email: jblee@uos.ac.kr Professional Website Dr. Lee https://www.myisrnn.org/arkadiusz-chworos daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/c5945bdf-d392-4132-b548-5794805e43bb/achworos-300x300.jpg Arkadiusz Chworos - Dr. Arkadiusz Chworos Email: achworos@cbmm.lodz.pl Professional Website Dr. Chworos https://www.myisrnn.org/david-gorenstein daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/31e904bd-5e37-4006-8e82-502accd54f4a/gorenstein_david.jpg David Gorenstein - Dr. David Gorenstein Email: David.gorenstein@am-biotech.com Professional Website Dr. Gorenstein https://www.myisrnn.org/daxiang-cui daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/4b2580a6-5ffc-41a7-9f7a-e5a9c8fe601f/daxiang+cui.jpg Daxiang Cui - Dr. Daxiang Cui Email: dxcui@sjtu.edu.cn Professional Website Dr. Cui https://www.myisrnn.org/ebbe-anderson daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/a7efd7af-c2f2-4bb0-9e46-6bc4b4a0b292/csm_Ebbe-2015-scale_5004638df3.jpg Ebbe Anderson - Dr. Ebbe Anderson Email: esa@inano.au.dk Aarhus University Website Dr. Anderson https://www.myisrnn.org/xandra-breakefield daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/778b14b9-cdba-4efc-a406-8f8d6c40df2b/breakfield-e1538574534790-150x150.jpg Xandra Breakefield - Dr. Xandra Breakefield Email: breakefield@hms.harvard.edu Aarhus University Website Dr. Breakefield https://www.myisrnn.org/thomas-hermann daily 0.75 2023-12-22 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/479d7144-7207-45af-9877-0f181ef4a0d3/1661476577628.jfif Thomas Hermann - Dr. Thomas Hermann Email: tch@ucsd.edu Professional Website Dr. Hermann https://www.myisrnn.org/wayne-miles daily 0.75 2024-01-03 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/e846ea5d-b9e8-4132-ba71-ad40ba43f52a/Wayne+Miles+%281%29.jpg Wayne Miles - Dr. Wayne Miles Email: wayne.miles@osumc.edu Professional Website The Ohio State University Website - Wayne Miles Education: Post-Doctoral fellow, Harvard Medical School, and Massachusetts General Hospital Cancer Center Graduate Student, The University of Manchester, United Kingdom Master of Science, Massey University, New Zealand Bachelor of Science, Massey University, New Zealand Experience: Associate Professor, Ohio State University Medical School Assistant Professor, Ohio State University Medical School Areas of Expertise: RNA Binding Proteins RB Tumor-suppressor gene Cancer Research Interest: Dr. Miles group is interested in understanding and then targeting RNA changes in cancers with inactivated tumor-suppressor genes including lung, thyroid, and hematopoietic tumors. Using genome editing and omics profiling, they define the post-transcriptional mechanisms that sustain tumor initiation, growth, and metastasis. Targeting these novel mechanisms requires adapting RNA nanomedicine. https://www.myisrnn.org/meetingreports daily 0.75 2024-06-18 https://www.myisrnn.org/become-a-member daily 0.75 2022-07-13 https://www.myisrnn.org/become-a-member/p/life-time-isrnn-member monthly 0.5 2022-07-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1657807308716-DVCVIIVEPMATK7BA1ERS/life+time+isrnn+2.jpg Become A Member - Life-time ISRNN member https://www.myisrnn.org/become-a-member/p/non-academic-isrnn-membership monthly 0.5 2022-07-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1657737964369-DRPJK29R59SKNIOADAPX/commerical+ISRNN+2.jpg Become A Member - Non-academic ISRNN membership https://www.myisrnn.org/become-a-member/p/full-isrnn-membership monthly 0.5 2022-07-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1657737833493-S1S7CRGSXW32LXF0COFD/FULL+ISRNN+2.jpg Become A Member - Full ISRNN Membership https://www.myisrnn.org/become-a-member/p/student-membership monthly 0.5 2022-07-14 https://images.squarespace-cdn.com/content/v1/62a78438c3f53c2929cee049/1657737644431-DRHHJJG1CBULMF2QAJC8/Student+ISRNN+2.jpg Become A Member - Student membership